Copy Link Print Information

GLPG1205

10 Cited Publications
Revisión del cliente

Based on 10 publication(s) in Google Scholar

GLPG1205 is potent, selective and orally active GPR84 (a G-protein-coupled receptor) antagonist with a favorable PK/PD profile. GLPG1205 has anti-inflammatory activity and is used for the treatment of pulmonary fibrosis. GLPG1205 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Para uso exclusivo en investigación. No vendemos a pacientes.

  • Pureza: 99.94%
  • No. CAS: 1445847-37-9
  • Fòrmula: C22H22N2O4
  • Peso molecular:378.42
  • Almacenamiento:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 2 years , -20°C, 1 year
  • GLPG1205 Chemical Structure
    GLPG1205 Chemical Structure
  • Experimental Validation Results for GLPG1205
  • Experimental Validation Results for GLPG1205
  • Experimental Validation Results for GLPG1205
  • Experimental Validation Results for GLPG1205
  • Experimental Validation Results for GLPG1205
No. CAS: 1445847-37-9
Tamaño
Precio
Stock
Cantidad
Amount: USD 0.00
Please select quantity
or
or

* Seleccione Cantidad antes de agregar artículos.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Encuentre su distribuidor local Your local distributor: Hycultec GmbHHycultec
  • Actividad biológica
  • Chemical Information
  • Solvente y solubilidad
  • Pureza y Documentación
  • Referencias
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) GLPG1205

More
Customer Validation & Images
Cell Proliferation/Viability AssayBio/Physico-chemical AssayIn Vivo Efficacy StudyHistological Imaging/StainingWB
  • Cell Proliferation/Viability Assay
  • In Vivo Efficacy Study
  • Bio/Physico-chemical Assay
  • Histological Imaging/Staining
  • WB
Keywords
MOQ
Minimum order quantity
100 mg

Obtener un presupuesto En stock

Other size
Obtener un presupuesto
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Inicie sesiòn
Registrar
Sign in to MedChemExpress
Registrar una cuenta nueva

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • GLPG1205 Chemical Structure
    GLPG1205 Chemical Structure
    1/16
  • 1/16

    GLPG1205 purchased from MedChemExpress. Usage Cited in: Cancer Immunol Res. 2026 Jan 20. [Abstract]

    Customer Validation
     Representative histogram and average proliferation from five independent biological replicates. Naïve CD8+ T cells were labeled with CFSE, activated, and treated for 72 hours. The results showed that the addition of GPR84 antagonist GLPG1205 (72 h) during activation resulted in a significant, dose-dependent increase in proliferation at 3 μmol/L (39.3%) and 10 μmol/L (71.7%).

  • 1/16

    GLPG1205 purchased from MedChemExpress. Usage Cited in: Cancer Immunol Res. 2026 Jan 20. [Abstract]

    Customer Validation
     Average tumor volumes and associated spider plots of B16-F10 tumor-bearing mice. Mice were administered a sham treatment or adoptively transferred activated pmel CD8+ T cells pretreated with DMSO or 10 μmol/L GLPG1205. Displayed results are obtained from one significant experiment. The results showed that pmel CD8+ T cells that were activated and treated with 10 μmol/L GLPG1205 prior to adoptive transfer elicited the best antitumor response, significantly better than the DMSO positive control or sham.

  • 1/16

    GLPG1205 purchased from MedChemExpress. Usage Cited in: Mol Med. 2025 May 14;31(1):187. [Abstract]

    Customer Validation
     WT mice were injected with Con A (15 mg/kg) for 1 h, treated with GLPG1205 or vehicle control by oral gavage, Serum ALT and AST levels were measured. n = 3–7 mice per group. The results showed that compared with the vehicle control group, serum ALT and AST levels were significantly reduced in the GLPG1205-treated mice, indicating that GLPG1205 effectively attenuated Con A-induced liver injury.

  • 1/16

    GLPG1205 purchased from MedChemExpress. Usage Cited in: Mol Med. 2025 May 14;31(1):187. [Abstract]

    Customer Validation
     WT mice were injected with Con A (15 mg/kg) for 1 h, treated with GLPG1205 or vehicle control by oral gavage. H&E staining was performed to assess liver tissue damage. The results showed that the area of ​​liver injury in the GLPG1205 group was significantly smaller than that in the vehicle control group.

  • 1/16

    GLPG1205 purchased from MedChemExpress. Usage Cited in: Mol Med. 2025 May 14;31(1):187. [Abstract]

    Customer Validation
     WT mice were injected with Con A (15 mg/kg) for 1 h, and treated with GLPG1205 or vehicle control by oral gavage. Bone marrow-derived macrophages (BMDMs) were pretreated with GLPG1205 for 1 h, followed by Con A treatment at 0 h, 0.5 h, 1 h, and 2 h. Western blotting was used to measure the expression of proteins involved in the STAT3, MAPK, and NF-κB signaling pathways. The results showed that, compared with the GLPG1205 group, the expression levels of p-STAT3, p-ERK, p-JNK, p-p38, and p-p65 were significantly elevated in the vehicle control group (Vehicle group).

  • GLPG1205